Medexus Pharmaceuticals Inc. (MEDXF)
MEDXF Stock Price Chart
Explore Medexus Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze MEDXF price movements and trends.
MEDXF Company Profile
Discover essential business fundamentals and corporate details for Medexus Pharmaceuticals Inc. (MEDXF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
27 Nov 2017
Employees
82.00
Website
https://www.medexus.comCEO
Kenneth d'Entremont
Description
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
MEDXF Financial Timeline
Browse a chronological timeline of Medexus Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.05, while revenue estimate is $34.96M.
Earnings released on 25 Jun 2025
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $17.38M , missing expectations by -51.65%.
Earnings released on 25 Jun 2025
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $24.62M , missing expectations by -29.26%.
Earnings released on 5 Feb 2025
EPS came in at $0.03 surpassing the estimated $0.02 by +50.00%, while revenue for the quarter reached $20.84M , missing expectations by -42.18%.
Earnings released on 7 Nov 2024
EPS came in at $0.00 surpassing the estimated $0.00 by +99.40%, while revenue for the quarter reached $19.38M , missing expectations by -51.70%.
Earnings released on 7 Aug 2024
EPS came in at $0.08 surpassing the estimated $0.04 by +100.00%, while revenue for the quarter reached $19.96M , missing expectations by -23.25%.
Earnings released on 25 Jun 2024
EPS came in at $0.03 surpassing the estimated $0.01 by +250.06%, while revenue for the quarter reached $19.12M , missing expectations by -28.77%.
Earnings released on 8 Feb 2024
EPS came in at -$0.02 falling short of the estimated -$0.01 by -158.73%, while revenue for the quarter reached $18.98M , missing expectations by -29.28%.
Earnings released on 8 Nov 2023
EPS came in at -$0.05 falling short of the estimated -$0.01 by -327.35%, while revenue for the quarter reached $22.39M , missing expectations by -25.93%.
Earnings released on 9 Aug 2023
EPS came in at $0.03 surpassing the estimated $0.01 by +349.78%, while revenue for the quarter reached $23.82M , missing expectations by -19.98%.
Earnings released on 21 Jun 2023
EPS came in at $0.34 surpassing the estimated -$0.05 by +780.00%, while revenue for the quarter reached $21.16M .
Earnings released on 8 Feb 2023
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $21.41M , missing expectations by -23.99%.
Earnings released on 8 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.21 by +33.33%, while revenue for the quarter reached $20.22M , missing expectations by -17.89%.
Earnings released on 8 Aug 2022
EPS came in at -$0.18 surpassing the estimated -$0.20 by +10.00%, while revenue for the quarter reached $17.89M , missing expectations by -17.85%.
Earnings released on 22 Jun 2022
EPS came in at -$0.23 surpassing the estimated -$0.30 by +23.33%, while revenue for the quarter reached $16.21M , missing expectations by -46.60%.
Earnings released on 9 Feb 2022
EPS came in at -$0.17 surpassing the estimated -$0.39 by +56.41%, while revenue for the quarter reached $16.68M , missing expectations by -10.96%.
Earnings released on 10 Nov 2021
EPS came in at -$0.32 surpassing the estimated -$0.53 by +39.62%, while revenue for the quarter reached $14.12M .
Earnings released on 16 Aug 2021
EPS came in at -$0.28 , while revenue for the quarter reached $13.93M .
Earnings released on 16 Jun 2021
EPS came in at -$0.21 falling short of the estimated -$0.02 by -950.00%, while revenue for the quarter reached $63.38M .
Earnings released on 1 Mar 2021
EPS came in at -$0.93 falling short of the estimated -$0.03 by -3.09K%, while revenue for the quarter reached $19.36M .
Earnings released on 16 Nov 2020
EPS came in at -$0.08 , while revenue for the quarter reached $13.26M .
MEDXF Stock Performance
Access detailed MEDXF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.